

JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation

Jong Sook Ahn^{1,2,3}, Juan Li^{1,2,3}, Edwin Chen^{2,3}, David G Kent^{2,3}, Hyun Jung Park^{2,3} and Anthony R Green^{2,3,4}

¹These authors contributed equally to this work

²Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, CB2 0XY, United Kingdom

³Department of Haematology, University of Cambridge, CB2 0XY, United Kingdom

⁴Department of Haematology, Addenbrooke's Hospital, Cambridge CB2 0QQ, United Kingdom

The authors declare no competing financial interests.

Address for Correspondence: Professor A.R.Green
Cambridge Institute of Medical Research
Hills Road, Cambridge CB2 0XY
United Kingdom
Telephone: (+44) 1223 336820
Fax: (+44) 1223 762720
E-mail: arg1000@cam.ac.uk

ABSTRACT

The JAK2V617F mutation is found in most patients with a myeloproliferative neoplasm (MPN). This gain-of-function mutation dysregulates cytokine signaling and is associated with increased accumulation of DNA damage, a process likely to drive disease evolution. JAK2V617F inhibits NHE-1 upregulation in response to DNA damage and consequently represses Bcl-xL deamidation and apoptosis, thus giving rise to inappropriate cell survival. However, the mechanism whereby NHE-1 expression is inhibited by JAK2V617F is unknown. In this study we demonstrate that accumulation of reactive oxygen species (ROS) in cells expressing JAK2V617F compromises the NHE-1/Bcl-xL deamidation pathway by repressing NHE-1 upregulation in response to DNA damage. In JAK2V617F-positive cells, increased ROS levels results from aberrant PI3K signaling, which decreases nuclear localization of FOXO3A and decreases catalase expression. Furthermore, when compared to autologous control erythroblasts, clonally-derived JAK2V617F-positive erythroblasts from MPN patients displayed increased ROS levels and reduced nuclear FOXO3A. [However](#), in hematopoietic stem cells (HSCs), FOXO3A is largely localized within the nuclei despite the presence of JAK2V617F mutation, suggesting that JAK2-FOXO signaling has a different effect on progenitors compared to stem cells. Inactivation of FOXO proteins and elevation of intracellular ROS are characteristics common to many cancers, and so these findings are likely to be of relevance beyond the MPN field.

Keywords: JAK2V617F; apoptosis; FOXO3A; Bcl-xL; DNA damage

Running title: FOXO3A/Bcl-xL deregulation by JAK2V617F suppresses apoptosis

INTRODUCTION

Forkhead box O (FOXO) transcription factors are evolutionarily conserved proteins involved in multiple physiological and pathological processes.¹ In mammals, three principle members of the FOXO subfamily (FOXO1, FOXO3A, FOXO4) are abundantly expressed in most tissues, where they promote cell cycle arrest, DNA repair, apoptosis, or detoxification of reactive oxygen species (ROS). In particular, FOXO3A has been shown to have an important role in hematopoiesis.²⁻⁵ The function of FOXO proteins is largely regulated by post-translational modifications, the main example of which is serine/threonine phosphorylation downstream of the PI3K/AKT signaling pathway.¹ Phosphorylated FOXO factors are exported from the nucleus to the cytoplasm and are targeted for proteasomal degradation. This regulation of FOXO proteins is disrupted in several tumor types including breast cancer, prostate cancer, glioblastoma, and chronic myeloid leukemia (CML).⁶

One of the major functions of FOXO proteins is to modulate ROS homeostasis by transcriptionally activating ROS detoxifying enzymes such as catalase and SOD.¹ Maintenance of appropriate levels of intracellular ROS is vital for signaling networks, which mediate multiple physiological processes.⁷ In several malignancies, perturbation of physiological ROS levels has been found to induce proliferation,⁸ amplify survival signalling,^{9,10} and limit anti-tumor cytotoxicity of various therapeutic agents,¹¹⁻¹³ therefore contributing to maintenance and progression of the cancer phenotype. Increased ROS is also a major cause of DNA damage, which leads to chromosomal abnormalities and genome instability.¹⁴ Regulation of ROS homeostasis by FOXO may therefore play a significant role in limiting cancer development and progression.

The myeloproliferative neoplasms (MPNs) are hematological malignancies associated with overproduction of mature, functional blood cells.¹⁵ These diseases are characterized by a chronic clinical course together with a risk of transformation to AML. In the majority of MPN patients, an acquired gain-of-function mutation (V617F) is found in JAK2, a cytoplasmic tyrosine kinase involved in signaling from multiple cytokine receptors. Cells expressing JAK2V617F harbor more DNA damage,¹⁶⁻¹⁹ and of particular note, the JAK2V617F mutation interferes with the normal apoptotic response to DNA damage,^{20,21} thus providing a mechanism for accumulation of DNA damage. In normal cells, DNA damage upregulates the Na⁺/H⁺ antiport NHE-1, thereby increasing intracellular pH, which in turn increases Bcl-xL deamidation and

promotes apoptosis. This pathway is inhibited by JAK2V617F in primary cells derived from MPN patients, thus permitting increased cell survival despite the presence of increased DNA damage²¹. However, the mechanism by which JAK2V617F inhibits NHE-1 upregulation remains unknown.

Here we demonstrate that JAK2V617F-mediated PI3K signaling inactivate FOXO3A in both JAK2V617F-expressing cell lines and hematopoietic progenitors from MPN patients and knock-in mice. We show that FOXO3A inactivation associates with increased intracellular ROS levels which in turn blocks the NHE-1/Bcl-xL pathway and therefore contributes to increased survival of JAK2V617F-expressing cells following DNA damage. These findings reveal a mechanism whereby JAK2V617F disrupts ROS homeostasis and reduces the normal apoptotic response to DNA damage. Finally, using hematopoietic stem cells (HSCs) and progenitors isolated from MPN patients and the JAK2V617F knock-in mice,²² we also demonstrate that FOXO3A activity downstream of JAK2V617F is distinct in HSCs compared to progenitors and more differentiated cells.

RESULTS

JAK2V617F elevates intracellular ROS levels and increases survival of JAK2V617F-positive cells following DNA damage

Elevated ROS can contribute to altered signal transduction as well as to transformation by a number of oncogenes. We therefore initially investigated the effect of JAK2V617F on intracellular ROS, using a cell-permeable fluorescent dye in IL3 or Epo-dependent Ba/F3-EpoR cells expressing wild-type JAK2 or the constitutively active JAK2V617F. Cells carrying JAK2V617F had higher levels of ROS compared to those cells expressing wild-type JAK2 (Figure 1A). We also examined the effect of endogenous JAK2V617F on ROS levels by using human erythroleukemia (HEL) cells, which harbors multiple copies of mutant JAK2.²³ Following the knockdown of JAK2V617F with siRNA (Supplementary Figure S1A), ROS levels were reduced compared to the cells transfected with a control siRNA (Figure 1B). Furthermore, treatment of HEL cells with the selective JAK2 inhibitor TG101209 also reduced ROS (Supplementary Figure S1B). Together these data indicate that exogenous and endogenous JAK2V617F are both associated with increased ROS levels.

As ROS levels modulate drug sensitivity in some cancers, we then determined the effects of elevated ROS on DNA damage-induced apoptosis. Following treatment with the DNA damage-inducing agent etoposide, Ba/F3-EpoR cells carrying JAK2V617F had reduced apoptosis compared to cells expressing wild-type Jak2 (Figure 1C). In addition, knockdown of endogenous JAK2V617F in HEL cells increased the sensitivity of these cells to etoposide treatment compared to the cells transfected with a control siRNA (Figure 1D). These data demonstrate that JAK2V617F increases cell survival following DNA damage.

JAK2V617F-induced increase in ROS mediates cell survival by inhibiting the NHE-1/Bcl-xL deamidation pathway

To determine if elevated ROS levels in JAK2V617F-positive cells directly contribute to increased survival following DNA damage, we used MitoQ, a potent antioxidant compound targeted specifically to mitochondria to reduce ROS levels (Figure 2A, [Supplementary Figure S2A](#)). Treatment of HEL or Ba/F3-EpoR cells with etoposide in the presence of MitoQ triggered significantly more cell death at all MitoQ concentrations tested compared to treatment with etoposide alone (Figure 2B, [Supplementary Figure S2B](#)). To confirm our results, we also expressed catalase in

HEL cells to reduce intracellular ROS levels. Compared to HEL cells transfected with a control construct, those transfected with a catalase expression vector showed an increase in catalase levels (Figure 2C), a small but significant reduction in ROS levels (Figure 2D) and increased apoptosis in response to etoposide (Figure 2E). Together these results indicate that elevated ROS levels induced by JAK2V617F contribute to increased survival of mutant cells following DNA damage.

Since elevated H₂O₂ levels have been shown to suppress both NHE-1 promoter activity and protein expression in non-hematopoietic cells,²⁴⁻²⁶ we investigated the possibility that the JAK2V617F-mediated increase in ROS levels might modulate the response of the NHE-1/Bcl-xL pathway to DNA damage. Cells with wild-type JAK2 normally respond to DNA damage by increasing NHE-1 expression, Bcl-xL deamidation leading to apoptosis, but these effects are abrogated by the presence of the JAK2V617F mutation.^{18,19} Consistent with these data, treatment with etoposide alone did not induce an increase in NHE-1 expression or Bcl-xL deamidation in JAK2V617F-positive HEL cells (Figure 2F-G). However, following catalase expression, the normal response to etoposide treatment was restored with induction of both NHE-1 upregulation and Bcl-xL deamidation (Figure 2F-G). These results demonstrate that reversing the JAK2V617F-mediated increase in ROS levels restores the response of NHE-1/Bcl-xL pathway to DNA damage.

JAK2V617F signaling reduces catalase expression and increases both phosphorylation and cytoplasmic sequestration of FOXO3A

As catalase is one of the main ROS detoxifying enzymes *in vivo*,²⁷ we next investigated the effect of JAK2V617F on endogenous catalase levels. Catalase expression was shown to be increased in HEL cells by either of two selective JAK2 inhibitors (Figure 3A) and also by siRNA knockdown of JAK2 (Figure 3B). Moreover, catalase expression was lower in Ba/F3-EpoR cells carrying JAK2V617F compared to the cells with wild-type JAK2 (Figure 3C). Unlike catalase, both Glutathione reductase and SOD2 expression was not increased in HEL cells treated with JAK2 inhibitor, but rather a reduction of SOD2 expression was observed. These data suggest that neither Glutathione reductase nor SOD2 is responsible for JAK2V617F induced ROS increase in this context and that the reduction of SOD2 expression may be a consequence of lowered ROS in the presence of JAK2 inhibitor (Supplementary Figure S3).

Since catalase expression is regulated by FOXO transcription factors,^{1,5} we next examined the possible role of JAK2V617F in modulating transcriptional activity of FOXO3A, the abnormal repression or deletion of which has been linked to hematological malignancies.²⁸⁻³⁰ In HEL cells, ser253 phosphorylation of FOXO3A was reduced by inhibiting JAK2V617F (Supplementary Figure S4A), indicating that JAK2V617F signaling leads to FOXO3A phosphorylation. Since the serine phosphorylation inactivates FOXO3A by excluding the protein from the nucleus and increasing its cytoplasmic sequestration,³¹ we investigated the sub-cellular localization of FOXO3A by immunofluorescence in HEL cells using an antibody to total FOXO3A. Nuclear localization of FOXO3A was significantly increased by two different JAK2 inhibitors (Supplementary Figure S4B) and also by siRNA-mediated JAK2 knockdown (Figure 3D). Furthermore, in Ba/F3-EpoR cells nuclear localization of FOXO3A was reduced by expression of JAK2V617F (Figure 3E) or by a JAK2 exon12 mutation, K539L (Supplementary Figure S5), but not by expression of wildtype JAK2.

Taken together these results demonstrate that JAK2V617F increases phosphorylation and cytoplasmic sequestration of FOXO3A, and that this is consequently associated with a reduction in catalase expression and an increase in intracellular ROS levels.

Inactivation of FOXO3A by JAK2V617F is mediated by PI3K signaling

In order to study the mechanism whereby FOXO3A is phosphorylated and inactivated downstream of JAK2V617F, we focused on the PI3K signaling pathway. This pathway is activated in JAK2V617F-positive cells³²⁻³⁴ and has been reported to phosphorylate FOXO transcription factors in various cell types.^{1,28,31} Treatment of HEL cells with either of two different PI3K inhibitors resulted in a significant increase in nuclear FOXO3A (Figure 4A). Inhibition of PI3K also increased catalase levels (Figure 4B), reduced intracellular ROS levels (Figure 4C) and increased etoposide-induced apoptosis (Figure 4D, E). [To investigate whether the increased apoptosis by PI3K inhibition was due to reduced ROS, apoptosis was analysed on cells treated with sodium azide, an irreversible inhibitor of catalase. The data indicate that an increase in etoposide-induced apoptosis by PI3K inhibition was reversed in the presence of sodium azide \(Figure 4D, E\), thus demonstrating that sensitization to DNA damage by PI3K inhibition is dependent on reduced ROS. Together, these data indicate that inactivation of FOXO3A by JAK2V617F is mediated by PI3K signaling.](#)

Nuclear localization of FOXO3A is reduced in clonally-derived JAK2V617F-positive erythroblasts from patients with a myeloproliferative neoplasm

The results described above demonstrate that JAK2V617F reduces nuclear localization of FOXO3A and increases ROS in cell lines. We next sought to determine if this is also true in primary cells from patients with JAK2V617F-positive MPNs. To this end, we studied 419 peripheral blood BFU-E colonies obtained from 3 patients with JAK2V617F-positive essential thrombocythemia (ET) or polycythemia vera (PV). Individual colonies were picked, genotyped for JAK2 mutation status and analyzed for FOXO3A localization and intracellular ROS levels. As both wild-type and mutant colonies were grown under identical conditions, this experimental strategy allowed a direct comparison of JAK2 wild-type and JAK2V617F-positive erythroblasts from the same patient.

In each patient, cells carrying the JAK2V617F mutation showed a significant reduction in the nuclear localization of FOXO3A compared to those with wild-type JAK2 (Figure 5A, B). From one of the PV patients, we obtained both JAK2V617F heterozygous and homozygous BFU-E colonies (Figure 5B, Patient 3) and observed a further reduction of nuclear FOXO3A in the homozygous cells compared to heterozygous cells. [It seems that in this patient](#) that dosage of mutant JAK2 signaling [correlates](#) the extent of FOXO3A cytoplasmic sequestration. In addition, ROS levels analyzed in 5 MPN patients were significantly higher in the erythroblasts from mutant BFU-E colonies compared to those from wild-type colonies (Figure 5C). These results are consistent with our cell line data and demonstrate that, in erythroblasts from MPN patients, the JAK2V617F mutation is also associated with increased cytoplasmic sequestration of FOXO3A and elevated ROS levels.

Nuclear localization of FOXO3A is not reduced by JAK2V617F in hematopoietic stem and early progenitor cells

We next studied HSCs to determine whether JAK2V617F also results in cytoplasmic sequestration of FOXO3A in HSCs. To this end we utilized JAK2V617F knock-in mice which carry human JAK2V617F and have a PV-like phenotype.²² In accord with our data from human erythroblasts, levels of nuclear FOXO3A were reduced in JAK2 mutant progenitors (CD150⁻CD48⁺CD45⁺) compared to littermate controls (Figure 6A). By contrast, [despite a mild increase in AKT phosphorylation \(Supplementary Figure S6\)](#), the levels of nuclear FOXO3A were not altered in mutant HSCs from the same mice ((HSCs: CD150⁺CD48⁻EPCR⁺CD45⁺),³⁵ Figure 6B)).

To confirm this finding in MPN patients, we isolated HSC-enriched population (HSCs; Lin⁻CD34⁺CD38⁻CD45RA⁻CD90⁺) and more mature progenitors (Lin⁻CD34⁺CD38⁺) from JAK2V617F-negative and JAK2V617F-positive patients [with very high mutant allele burden](#). Nuclear levels of FOXO3A were reduced in more mature progenitors from JAK2 mutant patients compared to those from JAK2 wild-type MPN patients (Figure 6C). However, in HSCs isolated from the same patients nuclear localization of FOXO3A was not altered by JAK2 genotypes (Figure 6D). Taken together, these results demonstrate that mutant JAK2 regulates nuclear localization of FOXO3A differently in primitive stem and progenitor cells, compared to more mature cells, with the latter showing a marked increase in the cytoplasmic sequestration of FOXO3A.

DISCUSSION

JAK2V617F has previously been shown to increase the rate of DNA damage^{16-19,36} and to inhibit DNA damage-induced apoptosis by repressing NHE-1 upregulation and Bcl-xL deamidation.^{20,21} These attributes combine to provide a potent mechanism for the accumulation of DNA damage thought to drive the progression of JAK2-mutated MPNs. However, the mechanism whereby JAK2V617F blocks NHE-1 upregulation has remained unknown. In this paper we demonstrate that JAK2V617F results in elevated intracellular ROS levels, which in turn inhibit the NHE-1/Bcl-xL pathway in response to DNA damage, thereby promoting cell survival. In addition, we show that the increased ROS levels associated with JAK2V617F reflect aberrant PI3K signalling and cytoplasmic sequestration of FOXO3A with consequent downregulation of catalase expression. **However**, FOXO3A nuclear localization is differentially modulated in more primitive haematopoietic stem and progenitor population.

Our data provides a mechanistic link between JAK2V617F and the inappropriate survival of cells harboring DNA damage (Figure 7). It is not clear how increased ROS levels repress NHE-1 expression, but one possibility is that a persistent pro-oxidative state, created by high ROS levels, inactivates the AP2 transcription factor, implicated in controlling NHE-1 expression,²⁴⁻²⁶ by modifying a thiol moiety in AP2 and thus inhibiting its DNA binding activity.³⁷ **Our data do not exclude the possibility that repression of pro-apoptotic genes by FOXO3A inactivation also contribute to resistance to DNA damage induced apoptosis. FOXO3A inactivation was reported to result in a transcriptional repression of pro-apoptotic BIM.²⁹ Nevertheless, our data do demonstrate that increased catalase expression and a reduction in ROS sensitize cells to apoptosis in the presence of DNA damage.**

The JAK2V617F mutation causes cytokine-independent activation of downstream signalling including the PI3K pathway³²⁻³⁴; however, the contribution of activated PI3K signalling to MPN pathogenesis is unclear. Previously, PI3K signalling has been shown to inactivate FOXO3A,^{28,31,38} the main FOXO protein operating in hematopoietic cells.^{3,4,39} We demonstrate that JAK2 mutations compromise FOXO3A function by PI3K-dependent cytoplasmic sequestration in hematopoietic progenitors and clonally-derived erythroblasts isolated from MPN patients as well as in cell lines. In addition, we show that JAK2V617F-induced inactivation of FOXO3A leads to reduced expression of catalase and, as a result, accumulation of intracellular ROS.

Consistent with our findings, Jak2V617F knock-in mice were shown to have reduced catalase level and elevated ROS.⁴⁰ However it remains possible that increased ROS in JAK2V617F positive cells may also be regulated by other pathways in addition to PI3K/FOXO3A.

Reactive oxygen species function as a “double-edged sword” and the association of ROS with cancer is both complex and paradoxical. While high levels of ROS that exceed the antioxidant capacity of the cell could trigger cell death, a moderate increase of ROS may promote cell survival. ROS levels are increased in many types of cancer cells and are associated with increased cell survival.⁴¹ Our data demonstrate that reduction of ROS sensitise cells to apoptosis in response to DNA damage. Consistent with our finding, Lin et al reported that antioxidant dihydromyricetin reduced ROS and promoted HepG2 cell apoptosis in a concentration-dependent manner.⁴² In addition, ROS are known to result in intrinsic DNA damage; increased DNA damage has previously been shown in cells from the JAK2V617F knockin mice and MPN patients and in cell lines expressing JAK2V617F.^{16-19,43} These data indicate that the JAK2V617F-mediated increase in ROS plays a dual role in promoting cell survival as well as accumulation of DNA damage. Furthermore, JAK2V617F has been reported to facilitate mutagenic DNA repair pathways,⁴⁴ which, together with elevated ROS, would potentiate genome instability and disease progression. Indeed, 5-30% of MPN patients can progress to leukemia that is associated with additional mutations in genes such as *TET2*, *DNMT3A*, and *ASXL1*.⁴⁵

Our findings therefore raise the possibility that JAK2V617F-mediated dysregulation of FOXO3A is critical in the pathogenesis of human MPNs. In accord with these data, FOXO3A^{-/-} mice were reported to exhibit a myeloproliferative phenotype³⁰. Our results also shed light on whether dysregulation of FOXO3A and increased ROS levels represent early or late events during tumorigenesis. MPNs are detected early, frequently following an incidental blood count, and provide a window on the earliest stages of malignancy that are inaccessible in most cancers. In particular, MPNs have not needed to acquire mutations associated with many aspects of the malignant phenotype (e.g. differentiation block, tissue invasion, growth in hypoxic environment). Our data therefore indicate that FOXO3A inactivation occurs early in the evolution of myeloid malignancies, an observation with implications for other cancers in which FOXO proteins are dysregulated.⁶

Our findings have several therapeutic implications for the treatment of MPNs and other malignancies. The addition of PI3K inhibitors significantly reduces the survival of JAK2V617F-positive cells following DNA damage, and reverses the altered ROS levels and FOXO3A localization. These data indicate that the PI3K pathway is critical for maintaining resistance to apoptosis in malignant cells. Furthermore, we found that counteracting the JAK2V617F-induced increase in ROS sensitizes the JAK2-mutant cells to a DNA damage-inducing agent. This is reminiscent of findings from other cancers where the combination of an antioxidant with chemotherapeutic interventions has been shown to be effective in killing drug-resistant tumours.¹¹⁻¹³ Malignant cells therefore seem to be sensitive to perturbation of the oncogene-mediated altered redox state, suggesting that these cells have adapted to and become dependent on increased ROS. Since increased activation of the PI3K pathway and elevated ROS levels are features common to many cancers, these findings may be relevant well beyond hematological malignancies.

FOXO3A inactivation has been previously reported in other haematological malignancies such as BCR-ABL positive chronic myeloid leukemia (CML). Similar to JAK2V617F, BCR-ABL activates PI3K pathway which in turn inactivate FOXO3A.^{28,46} BCR-ABL specific tyrosine kinase inhibitors (TKI) treatment led to rapid cytogenetic response in the majority of CML patients in chronic phase,⁴⁷ and this is associated with FOXO3A reactivation.⁴⁸ However numerous studies have demonstrated that TKIs cannot fully eliminate BCR-ABL transcripts and eradicate disease.⁴⁹⁻⁵¹ The mechanisms for TKI resistance of CML stem and progenitor cells are not entirely clear and it has been previously reported that primitive CML cells do not depend on BCR-ABL kinase activity for survival.^{52,53} One line of evidence suggest that the anti-proliferative effects of TKIs leads to an increase in quiescent CML stem and progenitor cells, making them difficult to target. Importantly, this effect was shown to be mediated by FOXO transcription factors.⁴⁸ Moreover, Naka et al. demonstrated that FOXO3A is predominantly localised in the nuclei of CML leukaemia-initiating cells (LICs) and that deletion of Foxo3a compromised the ability of LICs to initiate the disease in transplant recipients.⁵⁴ Together, these findings suggest that the function of FOXO transcription factors seem to depend largely on the context in which they are expressed. Consistent with this notion, JAK2 inhibitors also fail to eradicate primitive HSCs that carry the JAK2V617F mutation⁵⁵ and previous evidence has shown that JAK2V617F has distinct effects on the maintenance and proliferation of HSCs compared to progenitors.⁴³ As demonstrated in this study, FOXO3A is mainly localised in the nuclei of JAK2V617F-positive primitive HSCs. Nuclear FOXO3A in

mutant HSCs from MPN patients could potentially be responsible for drug resistance,⁵⁵ maintenance of quiescence,⁵ and/or alternatively, induction of protective autophagy under conditions of stress,⁵⁶ or efficient DNA repair possibly by interacting with ATM.⁵⁷ Thus our data suggest that MPN HSCs may be resistant to cellular stress in a Foxo-dependent manner. Patients with chronic phase MPNs lead normal lives, whereas accelerated phase disease is associated with a marked increase in morbidity and mortality. Prevention of disease evolution is therefore important and this study suggests that combinational therapies specific to HSCs together with JAK2 inhibitors are required to effectively eradicate the disease.

MATERIALS AND METHODS

Reagents

AT9283 and TG101209 were synthesized at Astex Therapeutics (Cambridge, UK). LY294002 was purchased from Cell Signaling (Hitchin, UK) and PI103 from Symansis (Buckingham, UK). MitoQ was kindly provided by Michael Murphy (MRC Mitochondrial Biology Unit, Cambridge, UK). All other reagents were purchased from Sigma (Poole, UK) unless otherwise stated.

Cell lines

HEL cells were cultured in RPMI supplemented with 10% fetal calf serum. HEL cells were treated with DMSO, 1 μ M AT9283, or 3 μ M TG101209 for 4 hours for JAK2V617F inhibition. Ba/F3-EpoR cells expressing wild-type or mutant JAK2 were maintained in RPMI with 10% fetal calf serum, 1 U/ml erythropoietin (R&D Systems, Abingdon, UK), and 0.5 mg/ml G418.

Mice

JAK2V617F knock-in mice were previously generated and reported.²² All mice were kept in specific pathogen free conditions and all procedures were performed according to rules of the Animal Welfare and Ethical Review Body (AWERB) and the UK Home Office regulations.

MPN Patients

MPN patients diagnosed with either essential thrombocythaemia or polycythaemia vera according to the World Health Organisation (WHO) criteria⁵⁸ were recruited from the MPN clinic at the Addenbrooke's Hospital in Cambridge, UK. Informed consent was given from all patient subjects. The work involving patient samples was approved by the Cambridge and Eastern Region Ethics Committee and was performed in accordance with the principles of the Declaration of Helsinki.

Analysis of BFU-E colonies

Venous blood samples (40 ml) were collected from each patient and peripheral blood mononuclear cells (PBMCs) were isolated using Lymphoprep (Axis Shield, Kimbolton, UK) according to the manufacturer's instructions. PBMCs (3×10^5 cells/ml) were then plated in methocult (H4531; Stem Cell Technologies, Grenoble, France) supplemented with 0.01 U/ml erythropoietin and cultured for 14 days at 37°C.

Individual BFU-E colonies were then plucked and resuspended in 30 μ l PBS, of which 2 μ l were used for genotyping by real-time qPCR to determine the JAK2 mutational status.⁵⁹ Colonies with JAK2V617F percentages of less than 10% were designated "wild-type", those between 40-60% "heterozygous", and those greater than 90% "homozygous".

Stem and progenitor cell isolation from MPN patients

PBMCs from MPN patients were washed with PBS supplemented with 2% fetal bovine serum (FBS) and 5mM EDTA and stored overnight at 4°C in PBS supplemented with 10% FBS and 5mM EDTA. Cells were then washed with PBS with 2% FBS and 5mM EDTA and spun at 300g for 7 minutes and the resulting pellets were treated with 50 μ l of 1mg/mL DNase I solution (STEMCELL Technologies) to avoid clumping. Cells were then depleted of differentiated hematopoietic cells using the EasySep Human Hematopoietic Progenitor enrichment kit (STEMCELL Technologies) with the following modifications: All samples were processed in 500 μ l of recommended medium for the first step, the progenitor enrichment cocktail was used at 5 μ l/mL cells, and the sample was only taken through one round of separation. Cells were then stained with antibodies to isolate the various progenitor compartments: anti-CD34 Per-CpCy5.5 (clone 581 Biolegend), anti-CD38 FITC (clone HIT2, BD Biosciences), anti-CD90 APC (clone 5E10, BD Biosciences), anti-FLK2 PE (clone BV10A4H2, Biolegend), anti-CD10 APC-Cy7 (clone HI10a, Biolegend), and anti-CD45RA Horizon V450 (HI100, BD Biosciences). HSCs were isolated as Lin⁻CD34⁺CD38⁻CD45RA⁻CD90⁺, progenitors as Lin⁻CD34⁺CD38⁺. Cells were sorted using a BD Influx sorter into tubes containing PBS supplemented with 10% FBS and EDTA.

JAK2 knockdown

HEL cells were transfected with either human JAK2 ON-TARGETplus SMARTpool or ON-TARGETplus Non-targeting Pool (control) (Dharmacon RNAi Technologies, UK). In detail, 5 μ l 20 μ M RNAi (either JAK2 or control) was mixed in 500 μ l opti-mem (Invitrogen, Paisley, UK) in tube A, and 5 μ l Lipofectamine was mixed in 500 μ l opti-mem (Invitrogen) in tube B. Both tubes were incubated at room temperature for 10 mins. Then the mixture of tube A and B were combined and incubated at room temperature for 30mins and added to 2mL HEL cells (1×10^6 cells in 6 well plate). Cells were collected 48 hours later for analysis.

Transfection and retroviral transduction

MSCV-neo based retroviral vectors MSCV-JAK2(WT)-neo, MSCV-JAK2V617F-neo, and MSCV-JAK2K539L-neo were transfected into 293T cells using FuGENE 6 Transfection Reagent (Roche Applied Science, Burgess Hill, UK) and culture supernatants were harvested 48 hours later. Viral infection of Ba/F3-EpoR cells was done by spinoculation (2000 rpm for 2 hours at 30°C) and the cells were cultured in RPMI with 10% fetal calf serum and 1 U/ml erythropoietin. G418 was added 2 days after infection to select for the transduced cells.

Immunofluorescence

Cytospin slides were fixed and permeabilized in 1:1 mixture of methanol and acetone. The slides were blocked for one hour at room temperature and then stained overnight at 4°C in 0.2% gelatine in PBS using primary antibody against FOXO3A (Cell signaling, 2497S, Hitchin, UK). For immunostaining of pAKT (Cell signalling, 4060S), the slides were blocked for one hour at room temperature in PBS / 5% normal serum / 0.3% Triton™ X-100) and then stained overnight at 4°C in PBS / 1% BSA / 0.3% Triton X-100. The secondary Alexa Fluor® 555-conjugated antibody (Life technologies, A-21428) was stained at room temperature for 1 hour in the respective primary antibody staining buffer. Nuclei were stained with 4', 6-diamidino-2-phenylindole (DAPI) (Vectashield, Burlingame, USA) and images were captured and scored blindly using ZEISS Axioskop2 mot plus fluorescence microscope equipped with a 40× Plan NEOFLUAR lens and an AxioCam MRm camera. Images were analysed using Isis software (Oxford Isis, Oxford, UK).

Real-time quantitative PCR

RNA was extracted using Tri reagent (Sigma) and real-time quantitative PCR was performed for human *NHE-1* expression using qPCR SYBR Green (Agilent Technologies UK Ltd., Workingham, UK) and Mx3000P™ Real-Time PCR system (Stratagene). The forward and reverse primers were 5'-TTGTTTTTGGGGAGTCCTTG-3' and 5'-ATGCCACACGTGTTTCGTAGTT-3'. Results were calculated using the delta-delta-Ct method with *ABL* as a control. The forward and reverse primers for *ABL* are 5'-GCGTGAGAGTGAGAGCAG-3' and 5'-TCTCGGAGGAGACGTAG-3'. *NHE1* expression in each sample was normalised to *ABL* expression and the relative *NHE1* expression in bar graph represents the relative levels to the pZeo-SV2(+) DMSO control which was normalized to 1.

Analyses of ROS and apoptosis

For ROS measurement, cells were stained with 10 μ M 2',7'-dichlorodihydrofluorescein diacetate (H₂DCF-DA, Invitrogen). For Ba/F3-EpoR cells, cells were stained with 5 μ M dihydrorhodamine 6G (Invitrogen) for 30-45 minutes at 37°C. Cells were then washed in PBS and the fluorescent signals were analyzed by FACS. To analyze apoptosis, cells were stained with Annexin V antibody (Biolegend) and 7-Aminoactinomycin D (7-AAD, Invitrogen) in Annexin V binding buffer (BD Biosciences).

Western blot analyses

Western blots on total cell lysates were performed using the following antibodies: anti-FOXO3A (Cell Signaling, [2497S](#)), phospho-FOXO3A (Ser319) (Cell Signaling, [9466S](#)), STAT5 (Santa Cruz, [SC-835](#)), phospho-STAT5 (Tyr694) (Cell Signaling, [9351S](#)), Catalase (Abcam, [ab16731](#)), Bcl-xL (BD Biosciences, 610212), anti-SOD2 (Life Technologies, MA1-106), anti-Glutathione reductase (Abcam, [ab128933](#)), β -actin (Sigma, [A2228](#)) and α -Tubulin (Sigma, [T9026](#)).

FACS sorting of mouse HSCs and progenitor populations

Mouse HSCs and progenitors were obtained from JAK2V617F knock-in mice²² and their littermate controls ([8-10 weeks old, age and sex matched mice in C57BL/6 background](#)) by FACS sorting of bone marrow MNCs. E-SLAM HSCs were isolated as previously described⁴³ with HSCs as CD150⁺CD48⁻EPCR⁺CD45⁺ and mature progenitors as CD150⁻CD48⁺CD45⁺.

Statistics

The statistical significance was determined by a 2-tailed, unpaired Student *t*-test.

CONFLICT-OF-INTEREST DISCLOSURE

The authors declare no competing financial interests.

ACKNOWLEDGEMENTS

The authors thank patients and staff of the Addenbrookes MPN clinic who have contributed samples to this study; Yvonne Silber for technical assistance; Philip Beer, Anna Godfrey, Christina Ortmann, and Joanna Baxter (Translational Research Laboratory, University of Cambridge) for help with acquiring clinical samples; Peter Campbell (Sanger Institute) for helpful discussions; and Michael Murphy (MRC MBU) for supplying MitoQ. Work in the Green lab is supported by Leukemia and Lymphoma Research, Cancer Research UK, the Kay Kendall Leukaemia Fund, the NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and the Leukemia & Lymphoma Society of America. DGK was supported by a postdoctoral fellowship from the Canadian Institutes of Health Research (Ottawa, ON), and a Lady Tata Memorial Trust International Award for Research in Leukaemia (London, UK). HJP was supported by a postdoctoral fellowship from the Human Frontier Science Program.

REFERENCES

FIGURE LEGENDS

Figure 1. JAK2V617F elevates intracellular ROS levels and increases survival following DNA damage. (A) JAK2V617F expression increase intracellular ROS in Ba/F3-EpoR cells. A representative flow cytometry histogram is shown and the bar graph shows mean fluorescence intensity (MFI) relative to that of the wild-type. (B) Knockdown of JAK2V617F reduces ROS in HEL cells. A representative flow cytometry histogram is shown and the bar graph shows DCF-DA MFI relative to that of the wild-type. (C) JAK2V617F expression in Ba/F3-EpoR cells increase cell survival following DNA damage. A representative flow cytometry plot is shown and the bar graph shows % of apoptotic cells. (D) Knockdown of JAK2V617F sensitizes cells to DNA damage-induced apoptosis. A representative flow cytometry plot is shown and the bar graph shows % of apoptotic cells. All data are averages of three independent experiments and shown as mean \pm SEM. ** $P < 0.01$ and *** $P < 0.001$.

Figure 2. Elevation of ROS levels by JAK2V617F increases resistance to DNA damage-induced apoptosis. (A) MitoQ treatment reduced ROS levels in HEL cells. Fold decrease in ROS levels following MitoQ treatment relative to the untreated culture is shown. (B) Reduced ROS restored sensitivity to DNA damage induced apoptosis in HEL cells. (C) Western blot shows Catalase expression in HEL cells transfected with an empty pZeo-SV2(+) or catalase expression construct pZeo-CAT. (D) Catalase expression in HEL cells (pZeo-CAT) reduced ROS levels. The bar graph shows mean fluorescence intensity relative to that of the wild-type. (E) Reduction of ROS levels increased apoptosis in the presence of DNA damage. (F) Reduction in ROS levels allows NHE-1 upregulation in HEL cells in response to DNA damage. (G) ROS reduction allows Bcl-xL deamidation in HEL cells in the presence of DNA damage. The upper bands (deamidated) and lower bands (native) were quantified using the Image J software and the deamidated protein was quantified as a percentage of total Bcl-xL. Data are shown as mean \pm SEM; $n=3$. * $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$.

Figure 3. JAK2V617F reduces nuclear localization of FOXO3A. (A) JAK2 inhibitors increased the expression of catalase in HEL cells. (B) JAK2V617F knockdown in HEL cells increased the expression of catalase. (C) Catalase expression was reduced in Ba/F3-EpoR cells carrying Jak2V617F compared to wildtype Jak2. (D) JAK2V617F knockdown induced nuclear localization of FOXO3A. Representative images are shown. Nuclear FOXO3A is shown as a percentage of

total FOXO3A. Numbers in parentheses indicate the numbers of cells analyzed for each samples. (E) Jak2V617F expression in BaF/3-EpoR cells increased cytoplasmic sequestration of FOXO3A compared to the wild-type. Data are mean \pm SEM. *** $P < 0.001$.

Figure 4. Inactivation of FOXO3A is mediated by the PI3K signaling pathway.

(A) Treatment with PI3K inhibitors relocalize FOXO3A to the nucleus in HEL cells. Representative pictures are shown on the left. Percentage of nuclear FOXO3A is shown on the right as an average of minimum 45 cells. (B) Western blot shows inhibition of PI3K increased in catalase expression. (C) Inhibition of PI3K reduced ROS levels. (D, E) Inhibition of PI3K increased the sensitivity of HEL cells to DNA damage-induced apoptosis and catalase inhibitor, sodium azide, reversed the sensitivity to apoptosis in response to DNA damage. All results are averages of three independent experiments and shown as mean \pm SEM. * $P < 0.05$, ** $P < 0.005$ and *** $P < 0.0005$.

Figure 5. JAK2V617F induces increased cytoplasmic sequestration of FOXO3A in erythroblasts from MPN patients.

(A) JAK2V617F causes increased cytoplasmic sequestration of FOXO3A in BFU-E colonies derived from MPN patients. Representative images are shown. (B) Reduced FOXO3A nuclear localization in cells carrying JAK2V617F compared to the cells with normal JAK2. Graph shows the data obtained from each patient (Patient 1: ET, heterozygous for JAK2V617F; Patient 2: PV, heterozygous for JAK2V617F; Patient 3: PV, both heterozygous and homozygous BFU-E clones for JAK2V617F). Numbers in parentheses indicate the numbers of cells analyzed for each samples. Data are mean \pm SEM. ** $P < 0.005$, *** $P < 0.0005$. (C) Mutant BFU-E colonies show increased ROS levels compared to the wild-type colonies. BFU-E colonies from five MPN patients were stained with DCF-DA. The data were normalised (WT=1) and relative fold increase is shown. A representative flow cytometry histogram is shown on the right. ** $P < 0.005$.

Figure 6. Mutant JAK2-FOXO3A signaling is different in stem cells compared to the progenitors.

(A) JAK2V617F induces an increase in the cytoplasmic sequestration of FOXO3A in the hematopoietic progenitors of JAK2V617F knock-in mice. (B) FOXO3A nuclear localisation is not altered in the nuclei of primitive HSCs in both wild-type and JAK2V617F-positive mice. Representative images are shown in the left panel and bar graphs show the mean percentages of nuclear FOXO3A in the

right panel. Numbers in parentheses indicate the numbers of cells analyzed from each mouse. (C) JAK2V617F induces an increase in the cytoplasmic sequestration of FOXO3A in the hematopoietic progenitors of MPN patients. WT1 and WT2: JAK2V617F-negative patients; VF1, VF2 and VF3: JAK2V617F-positive patients. Numbers in brackets indicate numbers of cells analyzed from each patient. (D) FOXO3A is in the nuclei of primitive HSCs in both JAK2V617F-negative and -positive patients. Data are mean \pm SEM. *** $P < 0.0005$.

Figure 7. Schematic pathway of JAK2V617F inhibition of the NHE-1/Bcl-xL regulated apoptosis. Upper panel shows a normal signaling pathway of apoptosis in response to DNA damage. Lower panel shows the dysregulated pathway in the JAK2V617F positive cells. Dashed lines illustrate other unidentified factors or pathways that may potentially regulate ROS and resistance to DNA damage induced apoptosis in JAK2V617F positive cells.









1. Calnan DR, Brunet A. The FoxO code. *Oncogene*. 2008;27(16):2276-2288.
2. Bakker WJ, van Dijk TB, Parren-van Amelsvoort M, et al. Differential regulation of Foxo3a target genes in erythropoiesis. *Mol Cell Biol*. 2007;27(10):3839-3854.
3. Miyamoto K, Araki KY, Naka K, et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. *Cell Stem Cell*. 2007;1(1):101-112.
4. Miyamoto K, Miyamoto T, Kato R, Yoshimura A, Motoyama N, Suda T. FoxO3a regulates hematopoietic homeostasis through a negative feedback pathway in conditions of stress or aging. *Blood*. 2008;112(12):4485-4493.
5. Tothova Z, Gilliland DG. FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. *Cell Stem Cell*. 2007;1(2):140-152.
6. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. *Oncogene*. 2008;27(16):2312-2319.
7. Pourova J, Kottova M, Voprsalova M, Pour M. Reactive oxygen and nitrogen species in normal physiological processes. *Acta Physiol (Oxf)*;198(1):15-35.
8. Weinberg F, Hamanaka R, Wheaton WW, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. *Proc Natl Acad Sci U S A*;107(19):8788-8793.
9. Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. *Leukemia*. 2009;23(8):1432-1440.
10. Chan DW, Liu VW, Tsao GS, et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. *Carcinogenesis*. 2008;29(9):1742-1750.

11. Rakshit S, Bagchi J, Mandal L, et al. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl⁺ cells by endothelial nitric oxide synthase-mediated production of nitric oxide. *Apoptosis*. 2009;14(3):298-308.
12. Sikora MJ, Bauer JA, Verhaegen M, et al. Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. *Cancer Biol Ther*. 2008;7(5):767-776.
13. Tsai SY, Sun NK, Lu HP, Cheng ML, Chao CC. Involvement of reactive oxygen species in multidrug resistance of a vincristine-selected lymphoblastoma. *Cancer Sci*. 2007;98(8):1206-1214.
14. Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM. Role of oxidatively induced DNA lesions in human pathogenesis. *Mutat Res*. 2010;704(1-3):152-159.
15. Campbell PJ, Green AR. The myeloproliferative disorders. *N Engl J Med*. 2006;355(23):2452-2466.
16. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. *Blood*. 2008;112(4):1402-1412.
17. Li J, Spensberger D, Ahn JS, et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. *Blood*. 2010;116(9):1528-1538.
18. Chen E, Ahn JS, Massie CE, et al. JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response. *Proc Natl Acad Sci U S A*. 2014;111(42):15190-15195.
19. Kagoya Y, Yoshimi A, Tsuruta-Kishino T, et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. *Blood*. 2014;124(19):2996-3006.
20. Zhao R, Oxley D, Smith TS, Follows GA, Green AR, Alexander DR. DNA damage-induced Bcl-xL deamidation is mediated by NHE-1 antiport regulated intracellular pH. *PLoS Biol*. 2007;5(1):e1.
21. Zhao R, Follows GA, Beer PA, et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. *N Engl J Med*. 2008;359(26):2778-2789.
22. Li J, Kent DG, Godfrey AL, et al. JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease. *Blood*. 2014;123(20):3139-3151.
23. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. *Leukemia*. 2006;20(3):471-476.
24. Kumar AP, Chang MK, Fliegel L, Pervaiz S, Clement MV. Oxidative repression of NHE1 gene expression involves iron-mediated caspase activity. *Cell Death Differ*. 2007;14(10):1733-1746.
25. Akram S, Teong HF, Fliegel L, Pervaiz S, Clement MV. Reactive oxygen species-mediated regulation of the Na⁺-H⁺ exchanger 1 gene expression connects intracellular redox status with cells' sensitivity to death triggers. *Cell Death Differ*. 2006;13(4):628-641.
26. Jhumka Z, Pervaiz S, Clement MV. Resveratrol regulates the expression of NHE-1 by repressing its promoter activity: critical involvement of intracellular H₂O₂ and caspases 3 and 6 in the absence of cell death. *Int J Biochem Cell Biol*. 2009;41(4):945-956.

27. Gaetani GF, Ferraris AM, Rolfo M, Mangerini R, Arena S, Kirkman HN. Predominant role of catalase in the disposal of hydrogen peroxide within human erythrocytes. *Blood*. 1996;87(4):1595-1599.
28. Komatsu N, Watanabe T, Uchida M, et al. A member of Forkhead transcription factor FKHL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells. *J Biol Chem*. 2003;278(8):6411-6419.
29. Essafi A, Fernandez de Mattos S, Hassen YA, et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. *Oncogene*. 2005;24(14):2317-2329.
30. Yalcin S, Marinkovic D, Mungamuri SK, et al. ROS-mediated amplification of AKT/mTOR signalling pathway leads to myeloproliferative syndrome in Foxo3(-/-) mice. *Embo J*. 2010;29(24):4118-4131.
31. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell*. 1999;96(6):857-868.
32. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature*. 2005;434:1144-1148.
33. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005;7(4):387-397.
34. Kralovics R, Passamonti F, Teo SS, et al. A gain of function mutation in Jak2 is frequently found in patients with myeloproliferative disorders. *New England Journal of Medicine*. 2005;352:1779-1790.
35. Kent DG, Copley MR, Benz C, et al. Prospective isolation and molecular characterization of hematopoietic stem cells with durable self-renewal potential. *Blood*. 2009;113(25):6342-6350.
36. Kagoya Y, Yoshimi A, Kataoka K, et al. Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. *J Clin Invest*. 2014;124(2):528-542.
37. Huang Y, Domann FE. Redox modulation of AP-2 DNA binding activity in vitro. *Biochem Biophys Res Commun*. 1998;249(2):307-312.
38. You H, Pellegrini M, Tsuchihara K, et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. *J Exp Med*. 2006;203(7):1657-1663.
39. Yalcin S, Zhang X, Luciano JP, et al. Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. *J Biol Chem*. 2008;283(37):25692-25705.
40. Marty C, Lacout C, Droin N, et al. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. *Leukemia*. 2013;27(11):2187-2195.
41. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? *Nat Rev Drug Discov*. 2009;8(7):579-591.
42. Lin B, Tan X, Liang J, et al. A reduction in reactive oxygen species contributes to dihydromyricetin-induced apoptosis in human hepatocellular carcinoma cells. *Sci Rep*. 2014;4:7041.
43. Kent DG, Li J, Tanna H, et al. Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion. *PLOS Biol*. 2013;11(6):e1001576.

44. Fernandes MS, Reddy MM, Gonneville JR, et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. *Blood*. 2009;114(9):1813-1819.
45. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. *Blood*. 2011;118(7):1723-1735.
46. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. *Proc Natl Acad Sci U S A*. 2003;100(11):6523-6528.
47. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *N Engl J Med*. 2006;355(23):2408-2417.
48. Pellicano F, Scott MT, Helgason GV, et al. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. *Stem Cells*. 2014;32(9):2324-2337.
49. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. *N Engl J Med*. 2003;349(15):1423-1432.
50. Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. *Blood*. 2011;118(20):5565-5572.
51. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. *Blood*. 2011;118(13):3657-3660.
52. Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. *J Clin Invest*. 2011;121(1):396-409.
53. Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. *Blood*. 2012;119(6):1501-1510.
54. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. *Nature*. 2010;463(7281):676-680.
55. Mullally A, Lane SW, Ball B, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. *Cancer Cell*. 2010;17(6):584-596.
56. Imai Y, Takahashi A, Hanyu A, et al. Crosstalk between the Rb pathway and AKT signaling forms a quiescence-senescence switch. *Cell Rep*. 2014;7(1):194-207.
57. Tsai WB, Chung YM, Takahashi Y, Xu Z, Hu MC. Functional interaction between FOXO3a and ATM regulates DNA damage response. *Nat Cell Biol*. 2008;10(4):460-467.
58. Swerdlow SH, Harris NL, Jaffe ES, Pileri SA, Stein H. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
59. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a

subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. *Blood*. 2006;107(10):4139-4141.

A**B****C****D****Figure 1**











Figure 2

A**B****C****D****E****Figure 3**







Figure 4

A**B****C****Figure 5**





Figure 6

Wild-type JAK2



JAK2 V617F




Figure 7